AMOYTOP(SH:688278)2024-03-28 16:00Financial Performance - The company's operating revenue for 2023 reached ¥2,100,322,880.68, representing a 37.55% increase compared to ¥1,526,905,123.64 in 2022[16]. - The net profit attributable to shareholders for 2023 was ¥555,449,411.27, a significant increase of 93.52% from ¥287,019,921.16 in the previous year[16]. - The net profit after deducting non-recurring gains and losses was ¥579,389,975.10, up 73.58% from ¥333,780,539.17 in 2022[16]. - The net cash flow from operating activities for 2023 was ¥512,100,798.56, reflecting a 41.01% increase from ¥363,160,688.75 in 2022[16]. - The company's total assets at the end of 2023 were ¥2,356,087,094.17, a 33.12% increase from ¥1,769,874,270.87 at the end of 2022[16]. - The net assets attributable to shareholders increased by 33.30% to ¥1,876,401,342.72 at the end of 2023, compared to ¥1,407,600,331.45 at the end of 2022[16]. - Basic earnings per share for 2023 were ¥1.37, a 92.96% increase from ¥0.71 in 2022[17]. - The company's operating revenue for 2023 reached 2.1 billion RMB, a year-on-year increase of 37.55%[23]. - Net profit attributable to shareholders increased by 93.52% year-on-year, reaching 555 million RMB[23]. - The net profit excluding non-recurring gains and losses grew by 73.58% year-on-year[23]. - The net cash flow from operating activities increased by 41.01% year-on-year[23]. Research and Development - The company's R&D investment for 2023 reached 280 million yuan, representing a year-on-year increase of 34.96%[25]. - The research and development expenditure accounted for 13.33% of operating revenue, a slight decrease of 0.26 percentage points from 13.59% in 2022[17]. - The company has established a comprehensive R&D system that combines independent and collaborative development to enhance innovation capabilities and product line diversity[34]. - The company has filed for 67 new patents during the reporting period, with a total of 289 patents filed to date, reflecting its commitment to innovation[49]. - The company is developing several innovative drugs, including AK0706 for chronic hepatitis B and ACT50 for tumor-related diseases, both currently in early clinical research stages[54]. - The YPEG-GH project completed Phase III clinical trials, with the drug registration application expected to be accepted in January 2024[26]. - The YPEG-EPO project is in the preparation stage for Phase III clinical research, aiming for market launch[53]. - The company has a strong focus on innovation, supported by a dedicated team and strategic talent acquisition efforts[58]. Product Development and Market Strategy - The newly approved drug "Peijin" (拓培非格司亭注射液) was launched on June 30, 2023, enhancing the company's product line and market competitiveness[25]. - The company is focused on expanding its product offerings and enhancing its market presence through innovative therapies and strategic initiatives[12]. - The company is advancing clinical trials for hepatitis B treatment, with a new indication application expected to be accepted by the National Medical Products Administration in March 2024[24]. - The company is collaborating with Aligos Therapeutics, Inc. on the development of oligonucleotide compounds for hepatitis treatment[24]. - The company plans to establish over 100 hepatitis B clinical cure outpatient clinics nationwide by 2025[24]. - The company aims to enhance the clinical cure rate for hepatitis B and reduce the risk of liver cancer through ongoing research and development efforts[39]. - The company is actively expanding its product offerings and market presence, with ongoing research and development efforts in new drug formulations[96]. Risk Management and Compliance - The company has detailed the risks faced during operations and corresponding countermeasures in the report[3]. - The company is implementing a risk management mechanism that includes risk identification, monitoring, response, and assessment[27]. - The company emphasizes compliance and integrity in investor relations, utilizing multiple channels for communication, including the "Shanghai Stock Exchange e-Interaction" platform and investor hotlines[193]. - The internal control system has been effectively implemented, with no significant defects found in financial and non-financial reports during the reporting period[164]. - The company has established a robust internal control management system to ensure compliance and safeguard investor interests, with no reported incidents of fund misappropriation or violations[132]. Shareholder Returns and Dividends - The proposed profit distribution plan for 2023 is to distribute a cash dividend of RMB 4.10 per 10 shares, totaling RMB 166,788,000, which accounts for 30.03% of the net profit attributable to shareholders[5]. - The company has a cash dividend policy that prioritizes cash distributions, with a minimum of 10% of the distributable profit allocated for cash dividends[160]. - The company emphasizes shareholder returns, adhering to a stable profit distribution policy since its listing, ensuring fair treatment of all shareholders, especially minority investors[185]. Environmental and Social Responsibility - The company invested ¥6.53 million in environmental protection measures during the reporting period[169]. - The company achieved ISO 14001 environmental management system certification during the reporting period[175]. - The company donated ¥15.98 million to public welfare projects, focusing on chronic hepatitis B treatment and awareness[181]. - The company supports various public welfare projects aimed at improving treatment for chronic hepatitis B patients, including the "Spring Rain Project" and "Qihang Project"[183]. - The company emphasizes energy efficiency and has implemented measures to reduce natural gas and electricity consumption[177]. Corporate Governance - All directors attended the board meeting, ensuring accountability for the report's accuracy[4]. - The company held its 2022 Annual General Meeting on April 27, 2023, and the resolutions were all approved without any rejections[135]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to CNY 19.76 million[145]. - The company has established an ESG governance structure, with a dedicated ESG working group reporting to the board[168]. - The company has a total of 163 party members, including 8 probationary members, ensuring a strong organizational foundation for high-quality development[191].